4D pharma (LBPSW) Stock Price, News & Analysis

Company Overview

4D pharma plc is a clinical-stage biotechnology company focused on the development of Live Biotherapeutics derived from the human microbiome. Leveraging its proprietary MicroRx discovery platform, the company identifies and refines strains of bacteria with potential therapeutic applications. These novel microbial candidates are formulated to support a range of indications, including gastrointestinal disorders, immuno-oncology and respiratory diseases.

The company’s pipeline features multiple programs at various stages of clinical development. Lead candidates include treatments for irritable bowel syndrome, antibiotic-associated diarrhea and inflammatory bowel disease, as well as immuno-oncology assets designed to enhance anti-tumor immune responses. 4D pharma pursues both in-house clinical programs and collaborative partnerships to advance these therapies, and it maintains a network of research alliances that support its R&D efforts.

Headquartered in Cardiff, Wales, 4D pharma operates additional research and development sites in the United States, Italy and Ireland. The company began trading its American Depositary Shares on the Nasdaq Stock Market under the ticker LBPSW, complementing its listing on the London Stock Exchange’s AIM market. Led by CEO Bethan James and an executive team with deep expertise in microbiome science and drug development, 4D pharma continues to build a global presence as it advances its live biotherapeutic offerings toward commercialization.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 20,931 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LBPSW
• CIK: 1830162
• Web: www.4dpharmaplc.com
• Phone: 441138950130
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $522 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A